These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28728166)

  • 1. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
    Itamochi H; Oishi T; Oumi N; Takeuchi S; Yoshihara K; Mikami M; Yaegashi N; Terao Y; Takehara K; Ushijima K; Watari H; Aoki D; Kimura T; Nakamura T; Yokoyama Y; Kigawa J; Sugiyama T
    Br J Cancer; 2017 Aug; 117(5):717-724. PubMed ID: 28728166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clearer view on ovarian clear cell carcinoma.
    De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
    Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
    Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT
    Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
    Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
    Chandler RL; Damrauer JS; Raab JR; Schisler JC; Wilkerson MD; Didion JP; Starmer J; Serber D; Yee D; Xiong J; Darr DB; Pardo-Manuel de Villena F; Kim WY; Magnuson T
    Nat Commun; 2015 Jan; 6():6118. PubMed ID: 25625625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
    Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
    Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
    [No Abstract]   [Full Text] [Related]  

  • 9. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
    Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
    Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.
    Li S; Meersma GJ; Kupryjanczyk J; de Jong S; Wisman GBA
    J Transl Med; 2024 Jun; 22(1):556. PubMed ID: 38858765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
    Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J
    Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
    Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience.
    Wijaya ST; Ngoi NY; Loh JW; Tan TZ; Lim D; Khan IS; Thian YL; Lai A; Ang BW; Tong P; Ng J; Low JJ; Ilancheran A; Lim SE; Lim YW; Tan DS
    J Gynecol Oncol; 2024 Sep; 35(5):e69. PubMed ID: 38606821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
    Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
    Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma.
    Marks EI; Brown VS; Dizon DS
    Am J Clin Oncol; 2020 Feb; 43(2):139-145. PubMed ID: 31764020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
    Jones S; Wang TL; Shih IeM; Mao TL; Nakayama K; Roden R; Glas R; Slamon D; Diaz LA; Vogelstein B; Kinzler KW; Velculescu VE; Papadopoulos N
    Science; 2010 Oct; 330(6001):228-31. PubMed ID: 20826764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
    Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
    Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C.
    Kolendowski B; Valdes YR; Hirte H; Itamochi H; Lee W; Carey M; Shepherd TG; DiMattia GE
    Cells; 2020 Nov; 9(11):. PubMed ID: 33153119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.